Anke Baum - Boehringer Ingelheim RCV

基本信息

浏览量：9

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 89 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Supplementary Data Table 3 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Birgit Wilding,Lydia Woelflingseder,Anke Baum, Krzysztof Chylinski, Gintautas Vainorius, Neil Gibson,Irene C. Waizenegger,Daniel Gerlach, Martin Augsten,Fiona Spreitzer,Yukina Shirai,Masachika Ikegami, Sylvia Tilandyová,Dirk Scharn,Mark A. Pearson,Johannes Popow,Anna C. Obenauf,Noboru Yamamoto,Shunsuke Kondo,Frans L. Opdam,Annemarie Bruining,Shinji Kohsaka,Norbert Kraut,John V. Heymach,Flavio Solca,Ralph A. Neumüller

crossref（2025）

引用0浏览0引用

Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Birgit Wilding,Lydia Woelflingseder,Anke Baum, Krzysztof Chylinski, Gintautas Vainorius, Neil Gibson,Irene C. Waizenegger,Daniel Gerlach, Martin Augsten,Fiona Spreitzer,Yukina Shirai,Masachika Ikegami, Sylvia Tilandyova,Dirk Scharn,Mark A. Pearson,Johannes Popow,Anna C. Obenauf,Noboru Yamamoto,Shunsuke Kondo,Frans L. Opdam,Annemarie Bruining,Shinji Kohsaka,Norbert Kraut,John V. Heymach,Flavio Solca,Ralph A. Neumueller

CANCER DISCOVERYno. 1 (2025): 119-138

引用0浏览0WOS引用

SOS1 Inhibition is an Effective Therapeutic Strategy in SOS1-mutant Cancer

Matthew J. Sale, Neal Mukherjee, Martin Koch,Regina Ruzicka,Robin Jacob,Christoph Albrecht, Teresa Zanin, Thomas Madensky,Robyn L. Schenk,Anke Baum,Kaja Kostyrko,Daniel Gerlach,Marco H. Hofmann,Frank McCormick

Cancer Researchno. 6_Supplement (2024): 2080-2080

引用0浏览0引用

Supplementary Table 2 from Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC

Eun Ji Lee,Seung Yeon Oh,You Won Lee,Ju Young Kim,Min-Je Kim, Tae Ho Kim,Jii Bum Lee,Min Hee Hong,Sun Min Lim,Anke Baum,Lydia Woelflingseder,Harald Engelhardt,Mark Petronczki,Flavio Solca,Mi Ran Yun,Byoung Chul Cho

crossref（2024）

引用0浏览0引用

Supplementary Figure S2 from Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC

crossref（2024）

引用0浏览0引用

Supplementary Figure S1 from Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC

crossref（2024）

引用0浏览0引用

Supplementary Table 1 from Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC

crossref（2024）

引用0浏览0引用

Supplementary Figure S3 from Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC

crossref（2024）

引用0浏览0引用

Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC

Eun Ji Lee,Seung Yeon Oh,You Won Lee,Kim Ju Young,Min-Je Kim, Tae Ho Kim,Jii Bum Lee,Min Hee Hong,Sun Min Lim,Anke Baum,Lydia Woelflingseder,Harald Engelhardt,Mark Petronczki,Flavio Solca,Mi Ran Yun,Byoung Chul Cho

CLINICAL CANCER RESEARCHno. 8 (2024): 1582-1594

引用2浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn